ImmunityBio, Inc. (IBRX)
NASDAQ: IBRX · Real-Time Price · USD
8.71
+0.92 (11.81%)
At close: Jun 26, 2026, 4:00 PM EDT
8.48
-0.23 (-2.64%)
After-hours: Jun 26, 2026, 7:59 PM EDT
ImmunityBio Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for ImmunityBio stock have an average target of 13, with a low estimate of 12 and a high estimate of 15. The average target predicts an increase of 49.25% from the current stock price of 8.71.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for ImmunityBio stock from 3 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 3 | 4 | 3 | 2 | 2 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 4 | 5 | 4 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $15 | Buy | Reiterates | $15 | +72.22% | Jun 2, 2026 |
| Piper Sandler | Piper Sandler | Buy Reiterates $12 | Buy | Reiterates | $12 | +37.77% | Jun 1, 2026 |
| BTIG | BTIG | Buy Maintains $13 → $12 | Buy | Maintains | $13 → $12 | +37.77% | May 8, 2026 |
Financial Forecast
Revenue This Year
222.38M
from 113.29M
Increased by 96.30%
Revenue Next Year
452.02M
from 222.38M
Increased by 103.26%
EPS This Year
-0.79
from -0.38
EPS Next Year
0.06
from -0.79
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 251.8M | 756.5M | |
| Avg | 222.4M | 452.0M | |
| Low | 198.2M | 283.1M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 122.3% | 240.2% | |
| Avg | 96.3% | 103.3% | |
| Low | 75.0% | 27.3% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | - | |
| Avg | -0.79 | 0.06 | |
| Low | - | - |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.